With Few Questions From FDA, Cinryze Seems Set For Smooth Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will review Cinryze only for prophylaxis of hereditary angioedema at Blood Products advisory panel meeting May 2, leaving open the possibility of a split indication.
You may also be interested in...
ViroPharma Looks To Enter HAE Market With Lev Acquisition
Pennsylvania biotech assumes FDA will split HAE orphan designation, with Cinryze winning prophylaxis indication first.
ViroPharma Looks To Enter HAE Market With Lev Acquisition
Pennsylvania biotech assumes FDA will split HAE orphan designation, with Cinryze winning prophylaxis indication first.
Lev’s Cinryze Wins Unanimous Advisory Committee Support
Postmarketing studies likely will be required for what could be the first U.S. treatment for hereditary angioedema.